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Abstract
Background: Activation of the Toll-like receptor (TLR) signaling pathway through TLR4 may be important in the induction of
protective immunity against Bordetella pertussis with TLR4-mediated activation of dendritic and B cells, induction of cytokine
expression, and reversal of tolerance as crucial steps. We examined whether single nucleotide polymorphisms (SNPs) in
genes of the TLR4 pathway and their interaction are associated with the response to whole-cell vaccine (WCV) pertussis
vaccination in 490 one-year-old children.
Methodology/Principal Findings: We analyzed associations of 75 haplotype-tagging SNPs in genes in the TLR4 signaling
pathway with pertussis toxin (PT)-IgG titers. We found significant associations between the PT-IgG titer and SNPs in CD14,
TLR4, TOLLIP, TIRAP, IRAK3, IRAK4, TICAM1, and TNFRSF4 in one or more of the analyses. The strongest evidence for
association was found for two SNPs (rs5744034 and rs5743894) in TOLLIP that were almost completely in linkage
disequilibrium, provided statistically significant associations in all tests with the lowest p-values, and displayed a dominant
mode of inheritance. However, none of these single gene associations would withstand correction for multiple testing. In
addition, Multifactor Dimensionality Reduction Analysis, an approach that does not need correction for multiple testing,
showed significant and strong two and three locus interactions between SNPs in TOLLIP (rs4963060), TLR4 (rs6478317) and
IRAK1 (rs1059703).
Conclusions/Significance: We have identified significant interactions between genes in the TLR pathway in the induction of
vaccine-induced immunity. These interactions underline that these genes are functionally related and together form a true
biological relationship in a protein-protein interaction network. Practically all our findings may be explained by genetic
variation in directly or indirectly interacting proteins at the extra- and intracytoplasmic sites of the cell membrane of
antigen-presenting cells, B cells, or both. Fine tuning of interacting proteins in the TLR pathway appears important for the
induction of an optimal vaccine response.
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Introduction
Whooping cough or pertussis is caused by the gram-negative
bacterium Bordetella pertussis. Vaccination with both whole-cell
(WCV) and acellular vaccine (ACV) limits the occurrence and
severity of pertussis, but is unable to completely prevent infection
and disease in vaccinated populations. Indeed, despite widespread
vaccination B. pertussis remains endemic and has even re-emerged
in many populations [1,2]. Previous studies provided evidence for
the role of the gene coding for Toll-like receptor 4 (TLR4) in both
the infection process (in mice), and the response to vaccination (in
mice and men) [3–10].
TLR4 was the first identified human Toll-like receptor that
belongs to a class of pathogen-associated molecular pattern
receptors on antigen-presenting cells, such as macrophages and
dendritic cells [11]. TLR4 is the receptor for bacterial lipopoly-
saccharide (LPS), and is also one of the receptors for pertussis toxin
(PT), one of the dominant virulence factors of B. pertussis [7,9,10].
LPS recognition by TLR4 on dendritic cells induces a proin-
flammatory response, including IL-12 which supports the
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have established that functional TLR4 is required for an early
interleukin (IL)-1b, tumor necrosis factor (TNF)-a, and interferon
(IFN)-c response that may enhance bacterial clearance, and thus,
despite the proinflammatory nature of these cytokines, may limit
pathology [3,8].
Signaling through TLR4 functions also in vaccine-induced
immunity to B. pertussis [6,13]. Whole cell pertussis vaccine
(WCV), which contains abundant LPS, can induce the develop-
ment of Th1- and Th17-cells in mice that mediate protective
cellular immunity to B. pertussis [6,13]. This response is abrogated
in Tlr4-defective mice. In contrast, protection induced with
acellular pertussis vaccine (ACV), which contains no or limited
LPS, was compromised, but not completely abrogated in Tlr4-
defective mice. In addition, we have observed that a lower PT-
specific antibody response is associated with the minor allele of a
single nucleotide polymorphism (SNP) (rs2770150) in TLR4 in
one-year-old WCV-vaccinated children [5]. Unfortunately the
functional significance of this SNP is still unknown. This antibody
response correlates with protection against disease both in humans
[14–16] and in mice [17].
TLR4 interacts with adaptor molecules, interacting proteins,
effectors, downstream pathways and target genes, which together
constitute the TLR signaling pathway. This pathway functions as a
complex, mutually coherent system of functionally interacting
molecules. Genes in such a pathway may be regulated together.
Indeed, array expression analysis of the Tlr-signaling pathway in B.
pertussis-infected mice revealed that 16 of the 47 genes within the
Toll-like receptor signaling pathway were regulated upon B.
pertussis infection [4]. Thus, the investigation of genetic associations
and gene-gene interactions in this pathway may provide novel
insights into the role of the TLR signaling pathway, and especially
of protein-protein interactions in this pathway, in the host response
to infection and vaccination.
The role of the TLR signaling pathway, and genetic variation
therein, in vaccine-induced immunity in humans has so far
received little attention [18], although TLR-mediated activation of
dendritic cells and B cells, induction of cytokine expression, and
reversal of tolerance are crucial steps in the induction of immunity.
Moreover, in addition to the microbial antigens in vaccines,
several vaccine adjuvants have now clearly been identified as TLR
ligands [19]. The current study therefore aims to provide further
insight into the role of genes and gene-gene interactions in the
TLR signaling pathway in the response to pertussis vaccination in
humans.
Materials and Methods
Study cohort
We collected capillary blood samples from 855 one-year-old
children from the KOALA Birth Cohort Study, the Netherlands.
The design and procedures of the KOALA cohort study have been
described previously [20]. Participants were asked to give written
informed consent to sampling of their infant’s buccal swab as
source of DNA, and capillary blood at the age of 1 year for the
determination of serologic parameters. All participants had signed
the informed consent. Ethical approval was obtained from the
medical ethics committee of the Maastricht University/University
Hospital of Maastricht. Genetic testing was included in the
medical ethical committee and informed consent procedures.
The children were vaccinated when they were 2, 3, 4, and 11
months old in the framework of the Dutch National Vaccination
Program. We selected 704 children of which the parents indicated
that they were vaccinated 4 times with WCV-containing diphteria-
tetanus-pertussis-polio-Haemophilus influenzae type B vaccine. Par-
ents were asked to collect buccal swabs for DNA from their child.
We determined genotypes in 522 children. We excluded 5 children
because their PT-IgG level was above 200 U/ml, which is
indicative for a natural infection [21]. We also excluded 23
children because their mother, or both mother’s parents were not
born in the Netherlands. A further 4 children were excluded
because less than 75% of their genotypes were available for
analysis. Thus, data from 490 children were available for analysis.
Antibody assay
The level of PT-specific immunoglobulin G (PT-IgG) was
determined by enzyme-linked immunosorbent assay on capillary
blood samples as described [21].
SNP selection and genotyping
Based on the recent literature and assisted by the online pathway-
visualization program Metacore
TM (http://www.genego.com/
metacore.php) we have made a selection of genes in the TLR
signaling pathway that could be associated with pertussis vaccine-
induced antibody responses (Fig. 1). Haplotype tagging SNPs were
selected from the HapMap database (http://www.hapmap.org/) or
from the Innate Immunity web site (http://www.innateimmunity.
net/datahomology) depending on the largest number of SNPs with
a minor allele frequency .0.1 available in each database. Because
pertussis vaccines may modulate the balance between Th1 and Th2
immunity [22], we further screened the biomedical literature until
October 2005 for SNPs within the candidate genes known to have
functional impact on, or to be associated with Th2 diseases, notably
asthma and atopy. SNPs were named according to the Human
Genome Variation Society guidelines (http://www.hgvs.org/
mutnomen/recs.html). Rs numbers have been derived from the
NCBI database (http://www.ncbi.nlm.nih.gov/sites/entrez).
Genomic DNA was extracted from buccal swabs or blood by
chloroform-2-propanolol extraction [23]. DNA was amplified by
using REPLI-g UltraFast technology (Qiagen
TM). Genotyping was
performed by Competitive Allele-Specific PCR using KASPar
TM
genotyping chemistry, performed under contract by K-Biosciences
(Cambridge, United Kingdom, http://www.kbioscience.co.uk).
Quality of genotype data was verified as described previously
[24]. Briefly, we verified the genotyping quality by three steps: 1) a
number of samples were genotyped in both genomic and amplified
DNA; 2) inheritance of alleles between parents and children was
checked using FBAT (http://biostat.harvard.edu); 3) genotype
data were analyzed for deviations from Hardy-Weinberg equilib-
rium using x
2 statistics. Comparison of genotypes between
genomic and amplified DNA and evaluation of inheritance
patterns between parents and children revealed an excellent
quality of the genotypes with a genotyping error of ,1%. Table 1
summarizes the genes and number of SNPs analyzed.
Statistical analyses
We used three parameters to examine genetic associations. First,
we compared cases and controls defined as children with PT-IgG
titers in the most extreme 10
th percentiles. Secondly, we performed
analyses with cases and controls defined as children with PT-IgG
titers in the most extreme 33
rd percentiles. The 10
th and 33
rd
percentiles reflect the values of the PT-IgG titers below or above
which 10 or 33 percent of the observations were found. The
highest and lowest 10
th percentiles (54 and 49 children
respectively) were chosen because we previously found a SNP in
TLR4 (rs2770150) associated with the lowest 10
th percentile (low
responders) compared to the highest 10
th percentile (high
responders) titer of PT-IgG (p=0.027) [5]. The highest and lowest
TLR Pathway in Vaccination
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rd percentiles (154 and 166 children respectively) were chosen to
obtain sufficient cases in the Multifactor Dimensionality Reduc-
tion (MDR) analyses. In addition we examined genetic association
with PT-IgG titers in a continuous analysis, because IgG titers
represent a continuous variable therewith circumventing arbitrary
cut-off values.
Data from 4 boys were excluded in the MDR analyses since
they had a heterozygous genotype for an IRAK1 SNP located on
the X-chromosome. Thus for the MDR analyses data from 153
and 164 children were available with PT-IgG in the lowest and
highest 33
rd percentiles, respectively.
After 10 based logarithmic transformation, the PT-IgG levels
were normally distributed according to Levene’s test (P.0.05). To
examine possible confounding factors, we tested for associations
between PT-IgG titer and the number of days between vaccination
and blood sampling and infant gender using Pearson correlation.
None of the factors tested influenced the PT-IgG level (P.0.05).
We examined whether SNPs were in Hardy Weinberg
equilibrium (HWE) using the chi-square test. As a result we
excluded the following SNPs because they showed a significant
deviation (p,0.001) from HWE: IRAK4 (rs146156), TOLLIP
(rs5743854), and TLR4 (rs10759931). Two SNPs in SIGIRR were
excluded because genotyping failed to give consistent results.
Therewith 75 SNPs were available for analyses. As indicated above
genotype dataonIRAK1 SNPs(located onthe X-chromosome)were
excluded from 4 boys who had a heterozygous genotype.
Univariate associations between genotypes and log PT-IgG
titers were assessed by analysis of variance (ANOVA). When
associations reached p-values,0.10, we further determined the
best fitting genetic model (co-dominant, dominant, recessive or
additive) in linear regression analysis. In addition we compared the
distribution of alleles and genotypes among individuals with IgG in
the highest 10
th or 33
rd percentiles with that of individuals with
IgG in the lowest 10
th or 33
rd percentiles using Pearson’s chi-
square test. To control for multiple testing, we calculated the false
discovery rate (FDR) according to Benjamini and Hochberg [25].
Gene-gene interactions were studied using Multifactor Dimen-
sionality Reduction (MDR version 1.0.0). MDR has been
Figure 1. Summary of the TLR pathway in antigen-presenting cells and the main results of this paper. TLRs recognize molecular
patterns associated with a broad range of pathogens including bacteria, fungi, protozoa and viruses. Vaccine components in WCV vaccine that may
be recognized by TLR4 include LPS and PT. Following TLR4 activation, both the MyD88 and TICAM1 routes, leading to the expression of
proinflammatory cytokines and type I IFNs respectively, may be activated. These promote the development of helper T cell responses providing T-cell
help to B cells. TLR signaling in B cells may further promote the generation of antibody responses and the maintenance of serologic memory.
TNFRSF4 is expressed on activated T cells. Adapted from BioCarta (http://www.biocarta.com/pathfiles/h_tollPathway.asp), KEGG (Kyoto Encyclopedia
of Genes and Genomes) [50], and Metacore
TM (http://www.genego.com/metacore.php).
doi:10.1371/journal.pone.0003665.g001
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reduces dimensionality of multifactor information to one dimen-
sion, i.e. high risk or low risk. First, the data are divided into a
training set (9/10 of the data) and an independent testing set (1/10
of the data). The model with the best classification error is selected
from the training set and the prediction error of that model is
estimated using the testing set. This procedure is repeated 10
times, and the model with the combination of loci that maximizes
the cross-validation consistency and minimizes the prediction error
is selected. Cross-validation consistency is a measure of the
number of times an MDR model is identified in each possible
group of nine-tenths of the subjects. To obtain sufficient cases we
performed MDR for individuals with IgG in the highest 33
rd
percentile defined as cases, and individuals with IgG in the lowest
33
rd percentile as controls. For MDR we excluded 5 SNPs
(rs2569190, rs5743894, rs5743859, rs5743987, and rs4986791)
that were in strong linkage disequilibrium (LD) with other SNPs
using a cut-off value of r
2.0.80. LD was calculated using the
software program Haploview. Because missing data are not
allowed in MDR, missing SNPs were imputed using multiple
imputation (MICE) [27]. MDR analyses were done separately
using 5 imputation files, and subsequently average testing
accuracies and cross-validation consistencies were calculated.
The model with the highest average cross validation consistency
and lowest average prediction error was selected as ‘‘best model’’.
Average cross validation consistency is the number of times the
model was selected as the best model after 10-fold cross-validation
runs. Average testing balanced accuracy is the accuracy of
classification of cases and controls in the testing dataset (one-tenth
of the data) calculated as (Sensitivity+Specificity)/2. To examine
the significance of testing accuracies, we determined 1,000 MDR
analyses for each test after permutation (200 of each imputation
file). The null-hypothesis was rejected when the one-sided p-value,
as estimated by 1,000 permutations in Monte Carlo simulation,
was ,5%. In that case the ‘‘best model’’ predicts the status of cases
and controls better than chance without the need to correct for
multiple testing. Interactions revealed by MDR analysis were
confirmed by linear regression (continuous data) and by logistic
regression (33
rd percentiles). Finally, interactions were visualized
by constructing an interaction dendrogram according to Moore et
al [28]. This dendrogram visualizes how much information about
case-control status is gained by combining two or more SNPs using
the MDR based on measures of entropy.
Results
Single gene associations
In total 9 haplotype-tagging SNPs in 8 genes were significantly
associated with PT-IgG levels (table 2). P-values were first
calculated without prior assumption of the mode of inheritance
(2 df). When p reached a value,0.10, the p-value belonging to the
best fitting genetic model was subsequently calculated. Table 3
gives odds ratios (ORs) belonging to the best fitting genetic model
for individuals in the highest 10
th or 33
rd percentile compared to
individuals in the lowest 10
th or 33
rd percentile, and table 4 shows
the PT-IgG titers of individuals with the indicated genotypes. The
results confirmed the association of a SNP (rs2770150) in TLR4 as
described by Banus et al [5], but only in the test that compares the
extreme 10
th percentiles. In addition we found associations
between PT-IgG titer with SNPs in CD14, TOLLIP, TIRAP,
IRAK3, IRAK4, TICAM1, and TNFRSF4. In the genetic models
the ORs for SNPs that showed association in one or more tests was
between 1.73 and 3.56 for alleles with a positive effect, and
between 0.28 and 0.45 for alleles with a negative effect (table 3),
indicating that individual genotypes appeared to have small to
moderately strong main effects. The three tests (continuous
analysis, 10
th and 33
rd percentiles) appeared to complement each
other, with the least number of associations found in the tests
comparing the highest and lowest 33
rd percentiles. Two TOLLIP
SNPs (rs5744034 and rs5743894) that were almost completely in
linkage disequilibrium (D’=1; r
2=0.986), gave statistically
significant associations in all three tests with the lowest p-values,
and displayed a dominant mode of inheritance. None of the SNPs
was significantly associated with the PT-IgG titer after controlling
for multiple testing by FDR analysis.
Gene-gene interactions
MDR analyses revealed two significant genetic interactions of
SNPs in TOLLIP (rs4963060), TLR4 (rs6478317; syn.: rs2737190)
and IRAK1 (rs1059703) with cases in the highest 33
rd percentile
compared to controls in the lowest 33
rd percentile of PT-IgG titers
(Table 5, Fig. 2a and Fig. 2b).
First, a combination of a TOLLIP SNP (rs4963060) and a TLR4
SNP (rs6478317) had a strong synergistic effect on PT-IgG titers
(p=0.01; average testing balanced accuracy 61%). The interaction
was confirmed by linear regression analysis for the level of PT-IgG
as the outcome (p-value for interaction term=0.01), and by logistic
regression analysis for the highest 33
rd percentile compared to the
lowest 33
rd percentile (p-value for interaction term=0.0005).
Figure 2 shows which combinations of genotypes have relatively
high levels of PT-IgG, i.e. dark shaded cells with a high ratio of
cases (left bars) and controls (right bars). Especially children with
wild type genotypes of both TOLLIP (rs4963060) and TLR4
(rs6478317) had a high chance of PT-IgG in the highest 33
rd
percentile (Fig. 2A, Fig. 3). The strong and significant interaction
Table 1. Genes and number of SNPs analyzed for association
with vaccine-induced PT-specific immunoglobulin B response.
Gene
Number of
haplotype-
tagging SNPs Description
LBP 8 LPS-binding protein
CD14 5 Monocyte differentiation antigen CD14
TLR4 8 Toll-like receptor 4
TOLLIP 14 Toll-interacting protein
TIRAP 5 TIR domain-containing adaptor protein
TICAM1 2 TIR domain-containing adaptor molecule 1
TICAM2 4 TIR domain-containing adaptor molecule 2
TRAF6 2 TNF receptor-associated factor 6
MYD88 2 Myeloid differentiation primary response gene 88
IRAK1 3 Interleukin 1 receptor-associated kinase 1
IRAK3 5 Interleukin 1 receptor-associated kinase 3
IRAK4 2 Interleukin 1 receptor-associated kinase 4
SOCS1 2 Suppressor of cytokine signaling 1
TNFRSF4 4 TNF receptor superfamily, member 4
TNFRSF14 2 TNF receptor superfamily, member 14
TNFRSF18 1 TNF receptor superfamily, member 18
TNFSF4 6 TNF ligand superfamily, member 4
Genes are named according to the nomenclature of the Human Genome
Organisation (HUGO) (http://www.hugo-international.org).
SNP: single nucleotide polymorphism.
doi:10.1371/journal.pone.0003665.t001
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was further indicated by a positive information gain based on
measures of entropy [28,29]. That is, information about case-
control status is gained above that provided by the SNPs
individually by combining the two SNPs (data not shown).
Second, an IRAK1 SNP (rs1059703) when added to the same
combination (TOLLIP rs4963060 and TLR4 rs6478317) further
increased the accuracy (table 5), and this combination was also
significantly associated with PT-IgG titers (p=0.01). However,
Fig. 2B shows that most of the interactive effect must be attributed
to TOLLIP and TLR4. Of note is that the SNPs showing genetic
interaction were not associated with the vaccine responses in
univariate analyses.
Discussion
Following earlier studies that provided evidence for the
involvement of TLR4 in vaccine-induced immunity to B. pertussis,
we elaborated on the role of genetic differences in other genes in
the TLR signalling-pathway. This approach was based on the
following. First, that TLR4 would likely function in a network of
molecules, together forming a molecular pathway. Second,
exploiting genetic differences in vaccine-induced responses in a
cohort of vaccinated children would constitute a feasible approach
to point to the functional role of genes that may be interesting to
study in follow-up studies. Third, genes that play a role in B.
pertussis vaccine-induced immunity may also be important in the
response to other vaccines or the pathobiology of infection.
Indeed, so far there is evidence that TLR4 affects both vaccine
responses, as well as the course of infection with gram-negative
bacteria and certain viruses, including respiratory syncytial virus
[3,5,6,30,31].
This study indeed indicated association of haplotype-tagging
SNPs in several genes in the TLR signaling pathway (CD14, TLR4,
TOLLIP, TIRAP, IRAK3, IRAK4, TICAM1 and TNFRSF4) with the
PT-specific antibody response following vaccination. This is an
interesting observation that needs nevertheless to be interpreted
with caution. Association between a gene polymorphism and a
phenotype in a genetic-epidemiological study may, in isolation,
convey little information about the causative role of the
Table 2. Single-nucleotide polymorphisms (SNPs) in genes from the TLR signaling pathway significantly associated with vaccine-
induced PT-immunoglobulin G.
Gene Rs-number Alleles
a MAF
b
continuous analysis
p-value
d
10
th percentiles
c p-
value
d
33
rd percentiles
c p-
value
d
CD14 rs5744455 T/C 0.24 0.03 0.12 0.02
TLR4 rs2770150 C/T 0.27 0.11 0.04 0.18
TOLLIP rs5744034 C/T 0.18 0.04 0.03 0.05
TOLLIP rs5743894 G/A 0.17 0.04 0.04 0.08
TIRAP rs8177376 G/T 0.24 0.08 0.05 0.31
TICAM1 rs1046673 T/C 0.15 0.06 0.07 0.12
IRAK3 rs3782347 G/A 0.28 0.51 0.08 0.61
IRAK4 rs4251520 C/T 0.12 0.07 0.02 0.28
TNFRSF4 rs17568 A/G 0.20 0.07 0.22 0.14
Bold p-values become ,0.05 for the best fitting genetic model.
a Minor allele first;
b MAF=minor allele frequency;
c highest versus lowest;
d P-values without prior assumption of the mode of inheritance (2 df).
doi:10.1371/journal.pone.0003665.t002
Table 3. Odds ratios of significantly associated genotypes with vaccine-induced PT-immunoglobulin G.
Gene Rs-number 10
th percentiles 33
rd percentiles
Best fitting genetic model
Odds ratio
a
(95% CI
b) p-value
Best fitting genetic
model
Odds ratio
a
(95% CI
b) p-value
CD14 rs5744455 NS recessive (TT vs. TC/CC) 0.28 (0.11–0.73) 0.009
TLR4 rs2770150 NS NS
TOLLIP rs5744034 dominant (CT/CC vs. TT) 2.93 (1.16–7.40) 0.02 dominant (CT/CC vs. TT) 1.79 (1.11–2.90) 0.02
TOLLIP rs5743894 dominant (GA/GG vs. AA) 2.68 (1.06–6.79) 0.04 dominant (GA/GG vs. AA) 1.73 (1.07–2.79) 0.03
TIRAP rs8177376 Additive
c (number of G alleles) 0.45 (0.23–0.87) 0.02 NS
TICAM1 rs1046673 NS NS
IRAK3 rs3782347 Additive
c (number of G alleles) 1.94 (1.01–3.73) 0.05 NS
IRAK4 rs4251520 dominant (CT/CC vs. TT) 3.56 (1.38–9.18) 0.009 NS
TNFRSF4 rs17568 NS NS
aOR belonging to the best fitting genetic model.
bConfidence interval.
cOn additive scale in a logistic regression model, i.e. multiplicative.
doi:10.1371/journal.pone.0003665.t003
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directly responsible for the phenotype, allelic association may
point to a polymorphism that is in close linkage disequilibrium to
the associated marker. Indeed, as the haplotype-tagging SNPs are
markers which capture most of the haplotypes in a region of
linkage disequilibrium, and most associated SNPs have an
unknown or no biologic function (summarized in Table 6), it is
likely that the observed associations refer to genetic haplotype
variation tagged by these SNPs. Such linkage disequilibrium, as
well as gene-environment interactions, might vary between
populations, and as a result association studies may yield
conflicting results [32]. In addition, multiple testing in association
studies may result in false discoveries, which necessitate the
development of strategies to underline the evidence of gene
involvement in a phenotype [33–35]. The single SNP associations
found in this study did not withstand correction for multiple testing
by FDR analysis (data not shown). Additional data are therefore
needed to corroborate our findings. These may be derived by
Table 4. Influence of single-nucleotide polymorphisms (SNPs) on vaccine-induced PT-immunoglobulin G titers.
Gene Rs-number Genotype Number
PT-IgG titer Geometric
Mean (95% CI) Best Model Ratio IgG titers (95% CI) p-value
CD14 rs5744455 CC 276 27.1 (25.2–29.0)
CT 168 25.8 (23.8–28.0) Recessive 0.76 (0.61–0.94) 0.01
TT 30 20.2 (16.7–24.3)
TLR4 rs2770150 TT 255 25.7 (24.0–27.6)
CT 198 27.3 (25.2–29.7) 0.11
CC 34 22.0 (18.5–26.3)
TOLLIP rs5744034 TT 321 24.9 (23.3–26.5)
CT 149 28.7 (26.3–31.4) Dominant 1.15 (1.03–1.28) 0.01
CC 11 26.6 (19.7–36.0)
TOLLIP rs5743894 AA 326 24.9 (23.3–26.5)
GA 146 28.7 (26.3–31.4) Dominant 1.14 (1.02–1.27) 0.02
GG 9 23.7 (17.3–32.5)
TIRAP rs8177376 TT 284 36.3 (29.5–44.4)
TG 168 28.4 (21.8–36.9) Additive 0.91 (0.84–0.99) 0.03
GG 32 18.7 (9.6–34.9)
TICAM1 rs1046673 CC 355 34.8 (29.0–41.7)
CT 117 27.3 (19.6–37.6) Additive 0.90 (0.81–0.99) 0.03
TT 12 11.4 (3.13–35.9)
IRAK3 rs3782347 AA 248 30.0 (23.8–37.7)
GA 202 34.0 (26.9–42.7) 0.51
GG 34 41.8 (22.7–74.2)
IRAK4 rs4251520 TT 372 29.5 (24.6–35.2)
CT 104 43.5 (31.0–60.3) Additive 1.14 (1.02–1.27) 0.02
CC 8 66.0 (8.3–366.8)
TNFRSF4 Rs17568 GG 302 33.9 (27.9–41.0)
GA 151 37.0 (27.3–49.6) Recessive 0.75 (0.58–0.96) 0.02
AA 21 13.8 (5.9–30.1)
doi:10.1371/journal.pone.0003665.t004
Table 5. Results of gene-gene interactions analyzed by MDR.
Genes and rs numbers
Average testing
balanced accuracy
a (%)
Average cross validation
consistency
b P
c
TOLLIP (rs5744034) 57 7.4 0.09
TOLLIP (rs4963060)*TLR4 (rs6478317) 61 6.4 0.01
TOLLIP (rs4963060)*TLR4 (rs6478317)*IRAK1 (rs1059703) 64 8.2 0.01
aAverage testing balanced accuracy is the accuracy of classification of cases and controls in the testing dataset (one-tenth of the data) calculated as
(Sensitivity+Specificity)/2.
bAverage cross validation consistency is the number of times the model was selected as the best model after 10-fold cross-validation runs.
cSignificance of accuracy (empirical p-value based on 1000 permutations).
doi:10.1371/journal.pone.0003665.t005
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PLoS ONE | www.plosone.org 7 November 2008 | Volume 3 | Issue 11 | e3665replication in other genetic-epidemiological studies, preferably in
combination with studies on the functional role of gene products
that provide biological plausibility. For example, it would be
interesting to know whether individuals genetically different in
TLR-pathway genes have altered proinflammatory cytokine
production upon vaccination. These data are unavailable for the
children from our cohort. However, in our murine model of wP
vaccination and B. pertussis challenge, Tlr4 enhanced the
production of the proinflammatory cytokines IL-1a, IL-1b, and
TNF-a [13].
The multiple testing problem does not apply to the strong
genetic interaction we found between SNPs in TLR4, TOLLIP,
and IRAK1. MDR chooses one best model from all possible
combinations of attributes. Subsequently we tested the estimated
accuracy of the best model for significance using the distribution of
accuracies of best models under the null-hypothesis obtained after
1000 permutations. Therefore, the problem of multiple signifi-
cance testing that inflates the type 1 error rate in single SNP
analyses does not apply to MDR analyses. These genetic
interactions therefore provide strong evidence that these genes
Figure 3. Influence of TOLLIP and TRL4 and their interaction on log PT-IgG titers. Influence of TOLLIP (rs4963060) and TLR4 (rs6478317)
interaction on log PT-IgG titers following pertussis vaccination in a dominant model of inheritance. The presence of one or two minor alleles of one of
these SNPs, but not the presence of one or two minor alleles of both SNPs, was associated with a lower PT-IgG titer. 0, 1, and 2 represent the number
of minor alleles. * Significantly different from the group homozygous for the wild-type alleles (p=0.04). P interaction term=0.01. Vertical bars indicate
standard errors.
doi:10.1371/journal.pone.0003665.g003
Table 6. Summary of locations and functional data of SNPs in genes from the TLR signaling pathway significantly associated with
vaccine-induced PT-immunoglobulin G.
Gene Rs-number Alleles
a Location Possible functional significance
CD14 rs5744455 T/C 2651 promoter
TLR4 rs2770150 C/T 23612 promoter
TLR4
b rs6478317 G/A 22570 promoter
TOLLIP rs5744034 C/T 34491, exon 6 39 UTR
TOLLIP rs5743894 G/A 5956, intron 1 intron
TOLLIP
b rs4963060 G/A 9668, intron 1 intron
TIRAP rs8177376 G/T 2822, exon 6 39 UTR
TICAM1 rs1046673 T/C 2148, 39 near gene 39 UTR
IRAK1
b rs1059703 T/C 12–36, intron 11; 6434, coding exon intron boundary; amino acid change 453 S/L
IRAK3 rs3782347 G/A 48836, intron 8 intron
IRAK4 rs4251520 C/T 13423, intron 8 intron
TNFRSF4 rs17568 A/G 2085, exon 5, amino acid position 178 synonymous mutation
a Minor allele first;
b associated in interaction.
Data are based on the NCBI database (http://www.ncbi.nlm.nih.gov/sites/entrez) and the Innate Immunity web site (http://www.innateimmunity.net).
doi:10.1371/journal.pone.0003665.t006
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PLoS ONE | www.plosone.org 8 November 2008 | Volume 3 | Issue 11 | e3665are indeed involved in the response to vaccination and work
together as functionally related genes in a single biological module.
We employed three different analyses, i.e. a continuous analysis
and analyses comparing study subjects with the extreme 10
th and
33
rd percentiles in PT-IgG titer. Though not independent, these
different analyses appeared to be complementary and confirma-
tory. The evidence of association was most consistent and strong
for the SNPs in the TOLLIP gene, which showed association in all
three analyses (at least at the genotype level) and also had the
lowest p-values (Table 2). A role of TOLLIP in vaccine-induced
immunity also appears plausible from its biological role and
interactions in the TLR signaling pathway. TOLLIP is a small
protein that binds the activated IL-1 receptor type I (IL-1RI)
complex, as well as TLR2 and TLR4 complexes [36,37]. TOLLIP
also suppresses IRAK-1’s kinase activity. In mice TOLLIP
deficiency results in attenuated responses of the proinflammatory
cytokines, IL-6, and TNF-a upon stimulation with IL-1ß and low
doses of LPS. TOLLIP therefore likely acts in ‘‘fine tuning’’ or
coordinating optimal signaling through IL-1RI and TLR4 [38].
We consider that physical interaction between TLR4, TOLLIP
and IRAK1 or their concerted regulation may explain the genetic
interaction of these genes. Although further work should proof that
the SNPs (or SNPs in linkage disequilibrium) affect the physical
interaction between these proteins, the agreement between
physical and genetic interaction between functionally relevant
genes within a single biological pathway is, to our knowledge, a
unique finding.
In addition to its interaction with TOLLIP, TLR4 together with
CD14 and the myeloid differentiation protein-2 (MD-2), forms a
pattern recognition receptor that plays an initiating role in the
innate immune response to LPS from Gram-negative bacteria.
The current view is that CD14 conveys LPS to the TLR4/MD-2
complex [39]. Evidently this cooperative function may explain the
genetic association of CD14 with the WCV vaccine response
found in this study. Previously genetic variation in another
promoter SNP in CD14 has been shown to affect pneumococcal
vaccine responsiveness in children. The T allele of the CD14 C-
159T polymorphism (rs2569190) was associated with increased
serum CD14 levels, and TT homozygotes showed higher serotype-
specific anti-pneumococcal vaccine IgG antibody levels [40].
The associations of TIRAP SNP rs8177376 and TICAM1 SNP
rs1046673 may also be explained by physical interaction or
concerted regulation between TIRAP and TICAM1 with
TOLLIP and TLR4. TIRAP and TICAM1 belong to the Toll/
Interleukin-1 receptor (TIR) domain-containing adaptors, also
including MyD88, that modulate TLR signaling pathways. TLRs
thus can activate two distinct branches of downstream signaling
pathways [41]. Our data suggest that both pathways are induced
following WCV pertussis vaccination.
The interleukin-1 receptor-associated-kinases (IRAKs) are
signal transduction mediators of the Toll and IL-1 receptor (IL-
1R) families. IRAK3 and IRAK4 showed evidence for association
in this study. These proteins may be involved in vaccine-induced
immunity because they regulate TLR signaling and innate
immune homeostasis [42].
Finally TNFRSF4 (syn. OX40 antigen, ACT35 antigen,
CD134) showed evidence for association. TNFRSF4 is a cell
surface antigen on T lymphocytes and a member of the tumor
necrosis factor/nerve growth factor receptor family [42,43].
Ligation of TNFRSF4 during T-cell-dendritic cell interaction is
crucial for clonal expansion of antigen-specific T-cells and
generation of T-cell memory [45]. Munks et al [46] found in
mice that stimulation of TNFRSF4 increased the number of
antigen-specific CD4 T cells following vaccination. Therefore it
was suggested that stimulants of TNFRSF4 (and other members of
its family) can improve the response to vaccination and may be
useful as vaccine adjuvants [46,47].
Together, the majority of our findings point to the significance
of directly or indirectly physically interacting proteins at the extra-
and intracytoplasmic sites of the cell membrane of antigen
presenting cells, or B cells, or both, in vaccine responsiveness. In
particular we have identified significant interactions between
TOLLIP, TLR4, and IRAK1. Further studies are required to
explain how and where the genetic associations and interactions in
the TLR pathway affect the PT antibody response. A T-dependent
antibody response is clearly a multi-step process, and the TLR
signalling pathway is likely involved in several of these steps. TLR
signalling induces dendritic cell maturation and helper T cell
activation, which are required to provide T-cell help to B cells.
This may occur directly, or indirectly via cytokines, including IL-
12 and TNF-a. In addition, activation of the TLR signaling
pathway in B cells may be helpful or required for the generation of
T-dependent antibody responses. This may occur by promoting
antigen presentation by antigen-specific B cells and by promoting
maturation of B cells into antibody-producing plasma cells [48]. In
addition, TLR signaling in memory B cells may contribute to the
maintenance of serological memory [49]. Altogether, we conclude
that our combined data are a strong indication for the involvement
of the TLR signaling pathway in the response to vaccination, as
well as for the cooperation of its genes in a functional interacting
network.
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